This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ThromboGenics To Benefit From Positive Ruling Regarding Patent Income Deduction

LEUVEN, Belgium, June 22, 2012 /PRNewswire/ --

Effective tax rate to be reduced significantly

ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announced that the Belgian tax authorities have granted the Company a positive ruling enabling it to benefit from the "patent income deduction regime" and, therefore, from a reduced tax rate for all patent-related ocriplasmin income.

The patent income deduction will apply to ThromboGenics' anticipated sales of ocriplasmin in the U.S. through its own commercial organization,  to the extent that  the revenues relate to the ocriplasmin patents. It will also apply to all upfront and milestone payments and royalties that ThromboGenics has or could receive from Alcon, its partner for the commercialization of ocriplasmin outside the U.S. As a result of this ruling ThromboGenics can exempt 80% of this qualifying patent-related income from the standard rate of Belgian corporate tax, after deducting depreciation of the ocriplasmin patents and certain royalty payments. As a result, the patent income deduction will lead to the Company's effective corporate tax rate being significantly lower than the standard Belgian corporate tax rate of 33.99%.

Chris Buyse, CFO of ThromboGenics, said: "Today's ruling is a very positive development for ThromboGenics and its shareholders. The patent income deduction regime is one of the Belgian government's key policies for promoting the development and competitiveness of research and development-based industries such as biotechnology. We are very pleased that we can benefit from this important government incentive to develop IP in Belgium starting in 2012 and that our tax rate will continue to be reduced significantly as we look to grow the global sales of ocriplasmin, in conjunction with our partner Alcon."

About the Belgian Patent Income Deduction

The patent income deduction regime was introduced by the Belgian government in 2007 to encourage Belgian companies to play an active role in patent research and development, as well as patent ownership.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,812.19 +19.51 0.11%
S&P 500 2,089.14 +2.55 0.12%
NASDAQ 5,102.8080 +0.33 0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs